Navigation Links
Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results

IRVINE, Calif., Oct. 25, 2012 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal first quarter ended September 30, 2012.


Pro-Dex, Inc. (the "Company") reported a loss from continuing operations of $59,000, or $0.02 per diluted share, for the quarter ended September 30, 2012 compared to income from continuing operations of $346,000, or $0.11 per diluted share, in the corresponding quarter in 2011.  The net loss for the quarter was $17,000, or $0.01 per diluted share, compared to net income of $446,000, or $0.14 per diluted share, in the year-ago period.  Sales for the quarter ended September 30, 2012 decreased 31% to $3.5 million from $5.0 million for the corresponding quarter in 2011.  As the Company has disclosed previously, the decrease in sales and the resulting net loss was primarily the result of a reduction in purchases of the Company's powered surgical products by its former largest customer.  Excluding sales to the former customer from the comparison of 2012 to 2011, the Company's surgical product sales increased $548,000 in 2012.  In addition, motion control system sales increased $138,000 in the 2012 quarter, when compared to the corresponding period in 2011.  The results from continuing operations for the 2012 and 2011 periods exclude the results of the Company's former Astromec product line, which was sold in February 2012 as previously announced. 

Gross profit for the quarter ended September 30, 2012 was $1.2 million, or 36%, compared to gross profit of $2.1 million, or 42%, for the year-ago period.  This decrease resulted primarily from the year-over-year decrease in sales and the related effects on manufacturing at lower sales volumes.

Operating expenses, which include selling, general and administrative, and research and development expenses, for the quarter ended September 30, 2012 decreased 26% to $1.3 million from $1.8 million in the prior year's corresponding quarter.  The decrease reflects the broad-based effect of the Company's cost-reduction efforts, evidenced by reductions of $100,000, or 27%, in selling expenses; $208,000, or 25%, in general and administrative expenses; and $155,000, or 28%, in research and development expenses.  All of these departmental reductions reflected, among other items, a focus on the elimination of non-critical activities, and the previously announced reductions in force and Company-wide 5% decrease in base compensation.

The Company also announced that, on September 24, 2012, it repaid in full the $685,000 outstanding balance of its term loan with Union Bank pursuant to the Company's previously announced termination of its credit facility agreement with the bank.

Michael J. Berthelot, the Company's President and Chief Executive Officer, commented, "We believe that the results of the first quarter of fiscal 2013, which is also the first full quarter under our new leadership, is the beginning of the beginning for our refocused company.  Several key programs came together quickly and have had immediate impact upon our business.  First, our focus on sales and improving our relationships with existing customers through reduced lead times and frame contracts resulted in us recognizing increases in revenues from our powered instrument product line of 25%, and 26% in total sales, when the $2.4 million of sales to our former largest customer in last year's first quarter are removed. Even further strengthening our backlog, the implementation of frame contracts resulted in us achieving a book-to-bill ratio of 1.14 for the first quarter.  Our gross margin for fiscal 2013's first quarter, at 36%, is the highest it has been since last year's first quarter and represents significant strengthening in our manufacturing cost structure and efficiency, especially when compared to the preceding quarter's gross margin of 23%.
The implementation of strict cost reduction policies in every department resulted in the previously mentioned 26% reduction in selling, general and administrative costs for the quarter when compared to last year's quarter and 17% when compared to the preceding quarter."

Mr. Berthelot continued, "All of these factors combined to result in our achieving first quarter EBITDA of $141,000, of which almost $100,000 was generated by continuing operations and the remainder was attributable to royalty payments from the buyer of our Astromec division.  This quarter was the first time in the last four quarters that we were able to achieve a positive EBITDA, even though our sales in the first quarter were lower than those of any of the three previous quarters. While one quarter makes neither a trend nor a year, we believe it shows that we are on the right path, and gives us the confidence to continue to pursue and execute our strategy."

"Operationally, we have made good progress on the four pillars on which we are building our recovery, Mr. Berthelot continued. "Our sales efforts have increased, we have begun three new customer/new product development projects, and we have several proposals out to medical device OEM's who could become significant customers if we are successful. Lined up behind those proposals we have a strong pipeline of projects in varying states of discussion.  Our sales and marketing team, with the support of our engineering and operations staffs, have done a superb job in moving from a standing start to a run.  Our lead times have been reduced significantly – to 6 weeks for our highest volume products from 16-18 weeks – and we believe we can continue to improve them.  As reflected in our stronger gross margin and lower SG&A expenses, our cost structure has come down not only as a result of reduced spending, but also as the result of increased participation by all of our associates in our efforts to operate more effectively and efficiently.  Lower power consumption, better scheduling, and identification of improved ways to do things all combine to benefit our customers, our associates, and our shareholders.  A stepped up program of internal testing, the design and implementation of automated test equipment, and the allocation of increased resources to engineering have improved the quality of our products and the confidence of our customers."

"During the first quarter we retired all of our outstanding debt, with the result that we now have a strong balance sheet with no debt and no intangible assets", said Mr. Berthelot.  "We will continue to pursue the sale of our former Astromec facility in Nevada and will increase our focus on working capital and cash flow generation as we consider the best means to deploy our cash balances to benefit all of our shareholders."

Teleconference Information:Investors and analysts are invited to listen to a broadcast review of the Company's fiscal 2013 first quarter financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company's website at  The conference call may also be accessed at Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Eastern Time) on November 8, 2012 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 402315.  An online archive of the broadcast will be available on the Company's website for a period of 365 days.

About Pro-Dex, Inc.:Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its OMS division designs and manufactures embedded motion control systems serving the medical, dental, semi-conductor and scientific research markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company's website at

Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)PRO-DEX, INC. and SUBSIDIARIES
September 30, 2012

June 30, 2012ASSETSCurrent assets:Cash


$ 4,112,000Accounts receivable, net of allowance for doubtful accounts of $10,000 at September 30, 2012 and $16,000 at June 30, 2012


1,581,000Other current receivables




2,791,000Prepaid expenses


172,000Income taxes receivable


609,000Deferred income taxes


109,000Total current assets


9,497,000Property, plant, equipment and leasehold improvements, net


2,539,000Real estate held for sale


733,000Other assets


53,000Total assets


2,822,000LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable


33,000Accrued expenses


1,425,000Income taxes payable


47,000Bank term loan


774,000Total current liabilities


2,879,000Non-current liabilities:Deferred income taxes


109,000Deferred rent


284,000Total non-current liabilities


393,000Total liabilities


3,272,000Commitments and contingenciesShareholders' equity:Common shares; no par value; 50,000,000 shares authorized; 3,307,350 and 3,272,350 shares issued and outstanding at September 30, 2012 and June 30, 2012, respectively


16,846,000Accumulated deficit


(7,296,000)Total shareholders' equity


9,550,000Total liabilities and shareholders' equity


For The Three Months Ended September 30,2012

2011Net sales

$   3,461,000

$ 5,045,000Cost of sales


2,937,000Gross profit


2,108,000Operating expenses:Selling expenses


374,000General and administrative expenses


816,000Research and development costs


561,000Total operating expenses


1,751,000Income (loss) from continuing operations before items below


357,000Other expense:Interest expense


(10,000)Total other expense


(10,000)Income (loss) from continuing operations before provision for income taxes


347,000Provision for income taxes


1,000Income (loss) from continuing operations


346,000Income from discontinued operations, net of provision for income taxes of $0 in 2012 and 2011


100,000Net income (loss)


446,000Per share data:Income (loss) from continuing operationsBasic




.11Income from discontinued operationsBasic




.03Net income (loss)Basic




.14Weighted average shares outstanding - basic


3,272,350Weighted average shares outstanding - diluted


For The Three Months Ended September 30,2012

2011Cash flows from operating activities:Net income (loss)


$  446,000Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:Depreciation and amortization


169,000Allowance for doubtful accounts


1,000Share-based compensation


12,000Changes in:Accounts receivable and other current receivables




(338,000)Prepaid expenses


(119,000)Other assets


8,000Accounts payable and accrued expenses


(616,000 )Income taxes receivable and payable


1,000Net cash provided by (used in) operating activities


349,000Cash flows from investing activities:Purchases of equipment


(42,000)Net cash used in investing activities


(42,000)Cash flows from financing activities:Principal payments on term loan


(89,000)Net cash used in financing activities


(89,000)Net increase (decrease) in cash


218,000Cash, beginning of period


4,689,000Cash, end of period

$   3,125,000

4,907,000Supplemental InformationCash payments for interest


,000Cash payments for income taxes


8212; PRO-DEX, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP DATA TO GAAP DATALoss From Continuing Operations Before Provision For Income Taxes

(in thousands)

(unaudited)For The Three Months Ended

September 30, 2012Earnings before interest, taxes, depreciation and amortization ("EBITDA")

$ 141Interest expense

(6)Depreciation and amortization

(151)Income from discontinued operations

(42)Loss from continuing operations before provision for income taxes


SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
2. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
3. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
6. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
7. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
8. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
9. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
10. Misonix Announces New Distribution Agreement For Panama
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 ... global pharmaceutical company, and Rugen Therapeutics, a start-up ... treatments for unmet CNS disorders and funded by ... that they have entered into an exclusive collaboration ... therapies for Autism Spectrum Disorders (ASD) and Obsessive ...
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
Breaking Medicine Technology:
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association ... their local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, ... day that inspires people to collaborate in improving their local communities and help ...
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital ... Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid ... health care services available to its members to help them make informed decisions ...
Breaking Medicine News(10 mins):